Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN EBITDA Margin
EBITDA as a percentage of revenue.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
EBITDA Margin · Q4 FY2025 · quarter ended Dec 2025
EBITDA Margin widens to 59.1%
EBITDA Margin was 59.1% in Q4 FY2025, up 111.5 pp from a year earlier. Over 3 fiscal years it widened by 24.1 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 66.7%
- Year-over-year change
- +35.3pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 66.7% | +35.3pp |
| FY2024 | 2024-12-31 | 31.4% | -2.4pp |
| FY2023 | 2023-12-31 | 33.8% | -8.8pp |
| FY2022 | 2022-12-31 | 42.6% | -14.7pp |
| FY2021 | 2021-12-31 | 57.3% | — |
EBITDA Margin vs competitors
How NNNN compares with its peers on the latest reported figures
- NNNN's FY2025 EBITDA Margin of 66.7% is the highest of the 10 companies compared; the peer median is -1.7%.
- Its year-over-year change of +35.3 pp is the 2nd highest of 9, against a peer median of +5.6 pp.
- Over three fiscal years its change of +24.1 pp compares with a peer median of +19.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | 66.7% | +35.3 pp | +24.1 pp |
| LTM Mar 2026 | 43.8% | +19.9 pp | +89.5 pp | |
| LTM Mar 2026 | 23.1% | +13.2 pp | +6.6 pp | |
| LTM Mar 2026 | 5.3% | +10.5 pp | +50.9 pp | |
| LTM Mar 2026 | 2.6% | +0.4 pp | +70.2 pp | |
| LTM Feb 2026 | -1.7% | -1.9 pp | -2.9 pp | |
| LTM Mar 2026 | -3.0% | +46.3 pp | -16.1 pp | |
| LTM Mar 2026 | -58.2% | +0.7 pp | +19.4 pp | |
| LTM Dec 2025 | -101.1% | — | — | |
| LTM Mar 2026 | -304.0% | -275.3 pp | — | |
| FY2025 | — | — | — | |
| Peer median (excluding NNNN) | -1.7% | +5.6 pp | +19.4 pp | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.43M | 23.54M | 6.71M | 8.19M | 9.76M |
| Cost of Revenue | 1.89M | 10.98M | 3.35M | 2.3M | 1.25M |
| Gross Profit | 2.54M | 12.56M | 3.36M | 5.89M | 8.51M |
| Gross Margin | 57.4% | 53.4% | 50.1% | 71.9% | 87.2% |
| Research & Development | 0 | 200K | 134.7K | 454.23K | 227.19K |
| Selling, General & Admin | 86.1K | 2.17M | 1.27M | 3.44M | 1.78M |
| Operating Expenses | 86.1K | 2.37M | 1.4M | 3.89M | 2M |
| Depreciation & Amortization | 0 | 6.25K | 13.04K | 0 | 0 |
| EBITDA | 2.54M | 10.03M | 2.27M | 2.57M | 6.51M |
| EBITDA Margin | 57.3% | 42.6% | 33.8% | 31.4% | 66.7% |
| Operating Income | 2.46M | 10.2M | 1.96M | 2M | 6.51M |
| Operating Margin | 55.5% | 43.3% | 29.2% | 24.4% | 66.7% |
| Interest Income | 0 | 42.25K | 165.34K | 337.51K | 160.28K |
| Interest Expense | 0 | 8K | 0 | 0 | 0 |
| Other Income / Expenses | 79.94K | (184.41K) | 292.78K | 377.48K | 717.46K |
| Income Before Tax | 2.54M | 10.01M | 2.25M | 2.37M | 7.23M |
| Pre-Tax Margin | 57.3% | 42.5% | 33.6% | 29.0% | 74.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | 2.54M | 10.01M | 2.25M | 2.37M | 7.23M |
| Net Margin | 57.3% | 42.5% | 33.6% | 29.0% | 74.1% |
| EPS (Basic) | 0.03 | 0.07 | 0.02 | 0.06 | 0.16 |
| EPS (Diluted) | 0.03 | 0.07 | 0.01 | 0.06 | 0.16 |
| Weighted Avg Shares | 100M | 143.89M | 143.89M | 42.29M | 43.89M |
| Weighted Avg Shares (Diluted) | 100M | 143.89M | 187.78M | 42.29M | 43.89M |
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.